Rich Segal

Partner, Cooley




Rich represents high growth companies, investment banks and institutional investors in equity and debt offerings, with a focus on the technology and life sciences sectors. Rich also regularly counsels public companies on SEC compliance and reporting matters, as well as private companies on a wide variety of corporate and securities matters. 

Rich has recently worked on completed securities offering by companies including: ADC Therapeutics, Akero Therapeutics, Akouos, argenx, Alarm.com, Appian, Avidity Biosciences, Cardlytics, The Clorox Company, COMPASS Pathways, DBV Technologies, Edgewise Therapeutics, Endava, Everbridge, fuboTV, Inventiva, iteos Therapeutics, Legend Biotech, Olink Holding, Prelude Therapeutics, Rapid7, Reata Pharmaceuticals, Schrodinger, Talaris Therapeutics, Vor Biopharma and Zentalis Pharmaceuticals. 

Rich regularly represents investment banks including: BofA Securities, Baird, Barclays, BMO, Canaccord, Cantor, Cowen, Citigroup, Credit Suisse, Deutsche Bank, Evercore, Goldman Sachs, H.C. Wainwright, Jefferies, JMP Securities, J.P. Morgan, Morgan Stanley, Needham, Normua, Oppenheimer, Piper Sandler, Raymond James, RBC, Stifel, SVB Leerink, UBS, Wedbush, Wells Fargo and William Blair. 

Rich is ranked by Chambers USA for Capital Markets in Massachusetts, where he is praised because β€œhe knows how to get deals done, has great judgment, and he understands the client really well.” In each of 2013 – 2021, Rich was named to the Massachusetts Super Lawyers Rising Stars list for his work in Securities & Corporate Finance. Richard was recognized as a Next Generation Partner in the 2021 edition of Legal 500.